Machine learning approach to identify phenotypes in patients with ischaemic heart failure with reduced ejection fraction.

AIMS

Patients experiencing ischaemic heart failure with reduced ejection fraction (HFrEF) represent a diverse group. We hypothesize that machine learning clustering can help separate distinctive patient phenotypes, paving the way for personalized management.

METHODS AND RESULTS

A total of 8591 ischaemic HFrEF patients pooled from the EPHESUS and CAPRICORN trials (64 ± 12 years; 28% women) were included in this analysis. Clusters were identified using both clinical and biological variables. Association between clusters and the composite of (i) heart failure hospitalization or all-cause death, (ii) cardiovascular (CV) hospitalization or all-cause death, and (iii) major adverse CV events was assessed. The derived algorithm was applied in the COMMANDER-HF trial (n = 5022) for external validation. Five clinical distinctive clusters were identified: Cluster 1 (n = 2161) with the older patients, higher prevalence of atrial fibrillation and previous CV events; Cluster 2 (n = 1376) with the higher prevalence of older hypertensive women and smoking habit; Cluster 3 (n = 1157) with the higher prevalence of diabetes and peripheral artery disease; Cluster 4 (n = 2073) with relatively younger patients, mostly men and with the higher left ventricular ejection fraction; Cluster 5 (n = 1824) with the younger patients and lower CV events burden. Cluster membership was efficiently predicted by a random forest algorithm. Clusters were significantly associated with outcomes in derivation and validation datasets, with Cluster 1 having the highest risk, and Cluster 4 the lowest. Mineralocorticoid receptor antagonist benefit on CV hospitalization or all-cause death was magnified in clusters with the lowest risk of events (Clusters 2 and 4).

CONCLUSION

Clustering reveals distinct risk subgroups in the heterogeneous array of ischaemic HFrEF patients. This classification, accessible online, could enhance future outcome predictions for ischaemic HFrEF cases.